Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma 16-10-2023, 19:21

Ferrari Releases Its 2022 Annual Report and Files Annual 25-02-2023, 04:08

Global Strategic Technology Leader Vahé Torossian Joins Builder.ai From Microsoft As President and Chief Partner Officer 16-01-2024, 19:00